Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Author Correction: Positive regulation of oxidative phosphorylation by nuclear myosin 1 protects cells from metabolic reprogramming and tumorigenesis in mice.
Venit T, Sapkota O, Abdrabou WS, Loganathan P, Pasricha R, Mahmood SR, El Said NH, Sherif S, Thomas S, Abdelrazig S, Amin S, Bedognetti D, Idaghdour Y, Magzoub M, Percipalle P. Venit T, et al. Among authors: bedognetti d. Nat Commun. 2023 Nov 30;14(1):7878. doi: 10.1038/s41467-023-43936-2. Nat Commun. 2023. PMID: 38036530 Free PMC article. No abstract available.
Positive regulation of oxidative phosphorylation by nuclear myosin 1 protects cells from metabolic reprogramming and tumorigenesis in mice.
Venit T, Sapkota O, Abdrabou WS, Loganathan P, Pasricha R, Mahmood SR, El Said NH, Sherif S, Thomas S, Abdelrazig S, Amin S, Bedognetti D, Idaghdour Y, Magzoub M, Percipalle P. Venit T, et al. Among authors: bedognetti d. Nat Commun. 2023 Oct 10;14(1):6328. doi: 10.1038/s41467-023-42093-w. Nat Commun. 2023. PMID: 37816864 Free PMC article.
Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer.
Mogenet A, Finetti P, Denicolai E, Greillier L, Boudou-Rouquette P, Goldwasser F, Lumet G, Ceccarelli M, Birnbaum D, Bedognetti D, Mamessier E, Barlesi F, Bertucci F, Tomasini P. Mogenet A, et al. Among authors: bedognetti d. J Transl Med. 2023 Sep 19;21(1):637. doi: 10.1186/s12967-023-04463-2. J Transl Med. 2023. PMID: 37726776 Free PMC article.
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.
Noviello TMR, Di Giacomo AM, Caruso FP, Covre A, Mortarini R, Scala G, Costa MC, Coral S, Fridman WH, Sautès-Fridman C, Brich S, Pruneri G, Simonetti E, Lofiego MF, Tufano R, Bedognetti D, Anichini A, Maio M, Ceccarelli M. Noviello TMR, et al. Among authors: bedognetti d. Nat Commun. 2023 Sep 22;14(1):5914. doi: 10.1038/s41467-023-40994-4. Nat Commun. 2023. PMID: 37739939 Free PMC article. Clinical Trial.
High-temporal resolution profiling reveals distinct immune trajectories following the first and second doses of COVID-19 mRNA vaccines.
Rinchai D, Deola S, Zoppoli G, Kabeer BSA, Taleb S, Pavlovski I, Maacha S, Gentilcore G, Toufiq M, Mathew L, Liu L, Vempalli FR, Mubarak G, Lorenz S, Sivieri I, Cirmena G, Dentone C, Cuccarolo P, Giacobbe DR, Baldi F, Garbarino A, Cigolini B, Cremonesi P, Bedognetti M, Ballestrero A, Bassetti M, Hejblum BP, Augustine T, Van Panhuys N, Thiebaut R, Branco R, Chew T, Shojaei M, Short K, Feng CG; PREDICT-19 Consortium; Zughaier SM, De Maria A, Tang B, Ait Hssain A, Bedognetti D, Grivel JC, Chaussabel D. Rinchai D, et al. Among authors: bedognetti m, bedognetti d. Sci Adv. 2022 Nov 11;8(45):eabp9961. doi: 10.1126/sciadv.abp9961. Epub 2022 Nov 11. Sci Adv. 2022. PMID: 36367935 Free PMC article.
136 results